Maltose Falsely Elevated Diabetics' Readings: FDA

Law360, New York (April 23, 2008, 12:00 AM EDT) -- The U.S. Food and Drug Administration said in a final report issued last week it had identified seven adverse events, including two deaths, in diabetic patients who received immune globulin products containing sugar maltose.

The agency released its report concerning maltose, which functions as a protein stabilizer and an osmotic agent, on April 17.

The agency's three-year investigation was launched in July 2005, when the FDA received a case report of an elderly male diabetic patient who received a 10% maltose-containing intravenous immune globulin product after...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.